Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with TP53 mutation at the EHA 2024 Annual Congress
Stockholm, June 15, 2024 - Immedica’s partner Actinium Pharmaceuticals, Inc. announced results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation in an oral presentation at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain. The Phase 3 SIERRA trial enrolled 153 patients with active relapsed or refractory acute myeloid leukemia (r/r AML) and compared outcomes of patients receiving Iomab-B and allogeneic haematopoietic stem cell transplantation (alloHSCT) to those of patients receiving physician's choice of
All 31 colorful versions of Tangente 38 date from NOMOS Glashütte are now in store. But not for long, as there is only 175 of each watch worldwideGLASHÜTTE, JUNE 17, 2024. The time has come: the complete collection of Tangente 38 date has arrived with selected retailers around the world. In honor of 175 years of watchmaking in Glashütte, there are exactly 175 examples of each version of the hand-wound mechanical watch. With 31 different color compositions, customers now have the luxury of choice when it comes to finding a watch that perfectly expresses their personality. This is because
